Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 13/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGAV | P06756 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22107463 | 0.71 | FGFR1 (0.43) | EP300FGFR1SLC22A6CYP2D6DNMT1 | |
| SCHEMBL19663379 | 0.69 | ALDH1A1 (0.53) | ITGB3ITGAV | |
| SCHEMBL19929 | 0.68 | — | — | |
| SCHEMBL27952255 | 0.68 | PIK3CB (0.41) | FGFR1SLC22A6 | |
| SCHEMBL2967556 | 0.68 | FGFR1 (0.43) | EP300FGFR1SLC22A6 | |
| SCHEMBL22219737 | 0.67 | KDM4E (0.35) | — | |
| SCHEMBL1892698 | 0.67 | FGFR1 (0.44) | EP300FGFR1SLC22A6 | |
| SCHEMBL23343373 | 0.67 | FGFR1 (0.44) | EP300FGFR1SLC22A6CYP2D6DNMT1 | |
| SCHEMBL24420503 | 0.67 | FGFR1 (0.40) | EP300FGFR1SLC22A6CYP2D6DNMT1 | |
| SCHEMBL28823315 | 0.67 | FGFR1 (0.40) | EP300FGFR1SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127300-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | OSAKA UNIVERSITY (JP) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127300-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | NT5C3B, DUT, RNGTT | EP300 4860/4885FGFR1 1774/4885SLC22A6 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.